Vir Biotechnology (VIR) to Release Earnings on Wednesday

Key Points

• Vir Biotechnology is expected to report its Q2 2025 earnings on August 6th, with analysts predicting an earnings loss of ($0.83) per share and revenue of $2.38 million.
• The company recently had a significant drop in revenue, with a 94.6% year-over-year decrease, reporting $3.03 million in the last quarter compared to an estimated $8.59 million.
• Despite a challenging financial landscape, several analysts maintain a positive outlook, with a consensus price target of $30.25 and seven buy ratings for the stock.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) is expected to post its Q2 2025 quarterly earnings results after the market closes on Wednesday, August 6th. Analysts expect Vir Biotechnology to post earnings of ($0.83) per share and revenue of $2.38 million for the quarter.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.05). The firm had revenue of $3.03 million during the quarter, compared to the consensus estimate of $8.59 million. Vir Biotechnology had a negative return on equity of 47.46% and a negative net margin of 2,769.04%. Vir Biotechnology's revenue was down 94.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.48) EPS. On average, analysts expect Vir Biotechnology to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Vir Biotechnology Price Performance

Shares of VIR traded down $0.04 on Friday, reaching $5.03. 809,884 shares of the stock traded hands, compared to its average volume of 1,124,994. The stock's 50-day moving average price is $5.30 and its 200-day moving average price is $6.62. The firm has a market cap of $695.35 million, a price-to-earnings ratio of -1.19 and a beta of 1.18. Vir Biotechnology has a 12 month low of $4.32 and a 12 month high of $14.45.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on VIR shares. Raymond James Financial began coverage on shares of Vir Biotechnology in a report on Friday, July 11th. They set an "outperform" rating on the stock. The Goldman Sachs Group reduced their price objective on Vir Biotechnology from $28.00 to $21.00 and set a "buy" rating on the stock in a report on Thursday, April 17th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $14.00 price objective on shares of Vir Biotechnology in a research note on Thursday, May 22nd. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $30.25.

Insider Transactions at Vir Biotechnology

In related news, Director Vicki L. Sato sold 22,000 shares of the company's stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $5.10, for a total transaction of $112,200.00. Following the completion of the transaction, the director directly owned 1,298,391 shares in the company, valued at $6,621,794.10. This represents a 1.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Mark Eisner sold 6,796 shares of Vir Biotechnology stock in a transaction dated Tuesday, July 15th. The shares were sold at an average price of $5.47, for a total value of $37,174.12. Following the sale, the executive vice president directly owned 108,204 shares in the company, valued at $591,875.88. The trade was a 5.91% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 35,582 shares of company stock worth $185,150 over the last quarter. Corporate insiders own 16.00% of the company's stock.

Institutional Investors Weigh In On Vir Biotechnology

Several institutional investors and hedge funds have recently made changes to their positions in VIR. Focus Partners Wealth lifted its holdings in shares of Vir Biotechnology by 15.3% in the first quarter. Focus Partners Wealth now owns 19,317 shares of the company's stock valued at $125,000 after purchasing an additional 2,566 shares in the last quarter. Acadian Asset Management LLC bought a new position in Vir Biotechnology in the 1st quarter valued at $335,000. Jacobs Levy Equity Management Inc. bought a new stake in shares of Vir Biotechnology during the 1st quarter worth $359,000. AQR Capital Management LLC grew its holdings in shares of Vir Biotechnology by 2,088.4% during the 1st quarter. AQR Capital Management LLC now owns 268,297 shares of the company's stock valued at $1,739,000 after purchasing an additional 256,037 shares during the last quarter. Finally, Woodline Partners LP boosted its holdings in Vir Biotechnology by 245.6% during the 1st quarter. Woodline Partners LP now owns 466,737 shares of the company's stock valued at $3,024,000 after acquiring an additional 331,701 shares during the period. Institutional investors own 65.32% of the company's stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).